Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lung cancer clue: could a DNA glitch open door to new treatments?

NCT ID NCT07303218

Knowledge-focused Sponsor: IRCCS San Raffaele Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at a specific DNA repair issue called homologous recombination deficiency (HRD) in people with a type of lung cancer (EGFR-mutated NSCLC). Researchers want to know how common HRD is and whether it relates to how the cancer behaves. They will also test this in lab models. The study does not give any experimental treatment—it just observes and analyzes samples from 100 participants.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If this study finds that HRD is common in this lung cancer type, it could point toward using PARP inhibitor drugs for these patients in the future.
What could go wrong
This is an observational study, not a treatment trial. It is small (100 people) and only at one hospital, so results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Dec 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients (≥18 years) with metastatic EGFR-mutated NSCLC eligible for treatment with EGFR-TKI according to standard clinical practice, with available tumor tissue suitable for HRD testing

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Participant is willing and able to give informed consent for participation in the study. However, since a part of the study is retrospective and, considering the large sample sizes required and considering that the disease involved in this study affects elderly subjects with co-morbidities and presents a significant mortality rate based on the stage of the disease, deceased and untraceable patients will also be included. 2. Age ≥18 years old 3. Have a metastatic histologically confirmed NSCLC 4. Presence of EGFR common mutations (i.e. ex19del and L858R) 5. Have sufficient biological material to assess genomic profiling with AmoyDx Focus panel or similar 6. Clinical data available Exclusion Criteria: 1. Insufficient baseline tumour tissue (unsuitable for HRD scoring) 2. Presence of EGFR uncommon mutations (i.e. ex20ins) 3. Known presence of co-occurring uncommon EGFRm, ALK, ROS1, or other main oncogenic drivers.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EGFR are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

DNA repair disease non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EGFR Homologous recombination deficiency Non-small cell lung cancer Parp inhibitor

Contacts and locations

Locations

  • Dept. Medical Oncology

    Milan, MI, 20132, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.